Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.

  title={Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.},
  author={Charles C. J. Carpenter and Margaret A. Fischl and Scott M. Hammer and Martin S. Hirsch and Donna M. Jacobsen and David A. Katzenstein and Julio S. G. Montaner and Douglas D. Richman and Michael S. Saag and Robert T. Schooley and Melanie Ann Thompson and Stefano Vella and Patrick G Yeni and Paul A. Volberding},
  volume={280 1},
OBJECTIVE To provide recommendations for antiretroviral therapy based on information available in mid-1998. PARTICIPANTS An international panel of physicians with expertise in antiretroviral research and care of patients with human immunodeficiency virus (HIV) infection, first convened by the International AIDS Society-USA in December 1995. EVIDENCE The panel reviewed available clinical and basic science study results (including phase 3 controlled trials; clinical, virologic, and… 

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.

New data have provided a stronger rationale for earlier initiation of more aggressive therapy than previously recommended and reinforce the importance of careful selection of initial drug regimen for each patient for optimal long-term clinical benefit and adherence.

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

New recommendations for HIV patient care include offering ART to all patients regardless of CD4 cell count, changes in therapeutic options, and modifications in the timing and choice of ART in the setting of opportunistic illnesses such as cryptococcal disease and tuberculosis.

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

Genotypic and phenotypic testing for HIV resistance to antiretroviral drugs may prove useful for individual patient management and need validation, standardization, and a clearer definition of their clinical roles.

Guidelines for antiretroviral therapy for HIV infection

Canadian guidelines for health care providers and their HIV-positive patients on the clinical use of antiretroviral agents for HIV infection are developed, subject to review and updating as new information on clinical benefits is published.

Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

IMPORTANCE New data and antiretroviral regimens expand treatment choices in resource-rich settings and warrant an update of recommendations to treat adults infected with human immunodeficiency virus

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.

IMPORTANCE New data and therapeutic options warrant updated recommendations for the use of antiretroviral drugs (ARVs) to treat or to prevent HIV infection in adults. OBJECTIVE To provide updated

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.

  • M. HirschH. Günthard D. Richman
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2008
A panel of physicians and scientists with expertise in drug-resistant HIV-1, drug management, and patient care is convened to review recently published data and presentations at scientific conferences and to provide updated recommendations on resistance testing.

HIV therapy guidelines.

Differences lie within the intepretation of this evidence and the expectation of long term benefit from current treatment regimens with the United States groups favouring earlier intervention and a heavier emphasis on the importance of plasma HIV RNA levels.

Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA.

Although the epidemiological features of CMV diseases are changing in the setting of potent, combination antiretroviral therapy, continued attention must be paid toCMV diseases in patients infected with the human immunodeficiency virus to prevent irreversible endorgan dysfunction.

Recovery of the immune system with antiretroviral therapy: the end of opportunism?

Potent antiretroviral therapy has become the standard of care for people with HIV infection, and its use has led to significant reductions in the incidence of the acquired immunodeficiency syndrome (AIDS) and in mortality from HIV infection.



Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel

Recent data on HIV pathogenesis, methods to determine plasma HIV RNA, clinical trial data, and availability of new drugs point to the need for new approaches to treatment, and therapeutic approaches need to be updated as new data continue to emerge.

Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000

Abstract These Guidelines were developed by the Panel* on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser

Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion

The objective was to compare plasma HIV-1 RNA with determinations of serum p24 antigen, neopterin, and 2-microglobulin levels and CD4+ T-cell counts as predictors of outcome in a cohort of homosexual men with documented HIV- 1 seroconversion.

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

Treatment-induced changes in the plasma HIV-1 RNA level and the CD4+ lymphocyte count are valid predictors of the clinical progression of HIV-related disease and can be used to assess the efficacy of zidovudine and possibly other antiretroviral drugs as well.

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.

Both the risk of the progression of HIV disease and the efficacy of antiretroviral therapy are strongly associated with the plasma level of HIV RNA and with the viral phenotype.

Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection

This study compared the prognostic value of plasma viral load with that of clinical, serologic, and cellular markers in a large cohort of HIV-infected men and incorporated the two most predictive markers-plasma viral load and CD4+ lymphocyte count-into a regression tree that is useful for assessing the prognosis of individual patients.

Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study.

The HIV- 1 RNA level during early chronic HIV-1 infection is a strong, age-independent predictor of clinical outcome; low levels define persons with a high probability of long-term AIDS-free survival.

Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

To prevent HIV-1 transmission, initiating maternal treatment with zidovudine is recommended regardless of the plasma level of HIV- 1 RNA or the CD4+ count, and the reduction in viral RNA from base line to delivery was not significantly associated with the risk of transmission.

Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.

The partial validation of HIV-1 RNA as a predictor for clinical end points has implications for the use of HIV -1 RNA in clinical trials and practice.

Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties.

Health care providers in North Carolina are identifying most of the state's HIV-seropositive pregnant women, treating them with zidovudine, and testing their infants soon after birth for HIV infection, which has reduced perinatal HIV transmission in the state.